197 related articles for article (PubMed ID: 9952266)
1. Adjustment of carbamazepine dose to offset the effects of the interaction with remacemide hydrochloride in a double-blind, multicentre, add-on drug trial (CR2237) in refractory epilepsy.
Mawer GE; Jamieson V; Lucas SB; Wild JM
Epilepsia; 1999 Feb; 40(2):190-6. PubMed ID: 9952266
[TBL] [Abstract][Full Text] [Related]
2. Mutual interaction between remacemide hydrochloride and carbamazepine: two drugs with active metabolites.
Leach JP; Blacklaw J; Jamieson V; Jones T; Richens A; Brodie MJ
Epilepsia; 1996 Nov; 37(11):1100-6. PubMed ID: 8917061
[TBL] [Abstract][Full Text] [Related]
3. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 800 mg/day) in a B.I.D. regimen.
Jones MW; Blume WT; Guberman A; Lee MA; Pillay N; Weaver DF; Veloso F; Holdich TA
Seizure; 2002 Mar; 11(2):104-13. PubMed ID: 11945097
[TBL] [Abstract][Full Text] [Related]
4. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen.
Chadwick DW; Betts TA; Boddie HG; Crawford PM; Lindstrom P; Newman PK; Soryal I; Wroe S; Holdich TA
Seizure; 2002 Mar; 11(2):114-23. PubMed ID: 11945098
[TBL] [Abstract][Full Text] [Related]
5. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients.
McKee PJ; Blacklaw J; Carswell A; Gillham RA; Brodie MJ
Br J Clin Pharmacol; 1993 Sep; 36(3):257-61. PubMed ID: 9114913
[TBL] [Abstract][Full Text] [Related]
6. Rapid switchover to carbamazepine using pharmacokinetic parameters.
Kanner AM; Bourgeois BF; Hasegawa H; Hutson P
Epilepsia; 1998 Feb; 39(2):194-200. PubMed ID: 9578000
[TBL] [Abstract][Full Text] [Related]
7. The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy.
Wesnes KA; Edgar C; Dean AD; Wroe SJ
Epilepsy Behav; 2009 Mar; 14(3):522-8. PubMed ID: 19111629
[TBL] [Abstract][Full Text] [Related]
8. Effects of add-on melatonin administration on antioxidant enzymes in children with epilepsy taking carbamazepine monotherapy: a randomized, double-blind, placebo-controlled trial.
Gupta M; Gupta YK; Agarwal S; Aneja S; Kalaivani M; Kohli K
Epilepsia; 2004 Dec; 45(12):1636-9. PubMed ID: 15571523
[TBL] [Abstract][Full Text] [Related]
9. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects.
Bareggi SR; Tata MR; Guizzaro A; Pirola R; Parisi A; Monza CG
Int Clin Psychopharmacol; 1994; 9(1):9-16. PubMed ID: 8195585
[TBL] [Abstract][Full Text] [Related]
10. Developmental and therapeutic pharmacology of antiepileptic drugs.
Miura H
Epilepsia; 2000; 41 Suppl 9():2-6. PubMed ID: 11156504
[TBL] [Abstract][Full Text] [Related]
11. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly.
Saetre E; Perucca E; Isojärvi J; Gjerstad L;
Epilepsia; 2007 Jul; 48(7):1292-302. PubMed ID: 17561956
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment.
Devinsky O; Vazquez B; Faught E; Leppik IE; Pellock JM; Schachter S; Alderfer V; Holdich TA
Seizure; 2002 Sep; 11(6):371-6. PubMed ID: 12160664
[TBL] [Abstract][Full Text] [Related]
13. Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients.
Leach JP; Girvan J; Jamieson V; Jones T; Richens A; Brodie MJ
Seizure; 1997 Jun; 6(3):179-84. PubMed ID: 9203245
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled, double-blind cross-over trial of adjunctive one month remacemide hydrochloride treatment in patients with refractory epilepsy.
Richens A; Mawer G; Crawford P; Harrison B
Seizure; 2000 Dec; 9(8):537-43. PubMed ID: 11162750
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy.
Garnett WR; Levy B; McLean AM; Zhang Y; Couch RA; Rudnic EM; Pellock JM; Belendiuk GW
Epilepsia; 1998 Mar; 39(3):274-9. PubMed ID: 9578044
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and cognitive effects of carbamazepine formulations with different dissolution rates.
Aldenkamp AP; Rentmeester T; Hulsman J; Majoie M; Doelman J; Diepman L; Schellekens A; Franken M; Olling M
Eur J Clin Pharmacol; 1998 Apr; 54(2):185-92. PubMed ID: 9626926
[TBL] [Abstract][Full Text] [Related]
17. Lack of interaction of gabapentin with carbamazepine or valproate.
Radulovic LL; Wilder BJ; Leppik IE; Bockbrader HN; Chang T; Posvar EL; Sedman AJ; Uthman BM; Erdman GR
Epilepsia; 1994; 35(1):155-61. PubMed ID: 8112239
[TBL] [Abstract][Full Text] [Related]
18. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.
Powell G; Saunders M; Marson AG
Cochrane Database Syst Rev; 2010 Jan; (1):CD007124. PubMed ID: 20091617
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
Baulac M; Rosenow F; Toledo M; Terada K; Li T; De Backer M; Werhahn KJ; Brock M
Lancet Neurol; 2017 Jan; 16(1):43-54. PubMed ID: 27889312
[TBL] [Abstract][Full Text] [Related]
20. Unblinded, randomized multicenter trial comparing lamotrigine and valproate combination with controlled-release carbamazepine monotherapy as initial drug regimen in untreated epilepsy.
Lee BI; No SK; Yi SD; Lee HW; Kim OJ; Kim SH; Kim MK; Kim SE; Kim YS; Kim JM; Lee SJ; Shin DJ; Park SP; Kim YI; Heo K; Cho YW; Cho YJ; Kim YN
Seizure; 2018 Feb; 55():17-24. PubMed ID: 29324401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
